CanadianCannabisWire LimeLight of The MONTH is
 

InMed Pharmaceuticals Inc.
(NASDAQ: INM)

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the development, manufacture and commercialization of rare cannabinoids for pharmaceutical and consumer health and wellness applications. InMed is a clinical stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab.

In October 2021, InMed announced its acquisition of BayMedica Inc., a private U.S. firm specializing in the manufacture and commercialization of rare cannabinoids for the health and wellness sector. BayMedica, now operating as a subsidiary of InMed, is a revenue-stage biotechnology firm leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa (EB), a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. A Phase 2 clinical trial in EB is currently underway, marking the first time that a CBN-based formulation has advanced to a Phase 2 clinical trial. The study is taking place at 13 sites across eight countries in Europe, with patient screening and treatment currently ongoing.

InMed is also developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Investment Considerations

• InMed has a world class leadership team with a successful track record of drug development and commercialization.
• InMed has a solid and expanding intellectual property portfolio with multiple patents filed.
• The company recently acquired rare cannabinoids manufacturer BayMedica.
• InMed retains all commercial rights to its IntegraSyn manufacturing system.
• InMed has commenced a Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa.
• The consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029.

Recent Coverage:
 

InvestorNewsBreaks - InMed Pharmaceuticals Inc. (NASDAQ: INM) Issues Update on Phase 2 EB Trial

July 25, 2022 8:30 AM

• Phase 2 clinical trial recently expanded to include adolescents following independent review of early safety data
• First adolescent patient with EB enrolled into clinical trial and completed treatment
• International patent granted for the use of cannabinol for the treatment of epidermolysis bullosa

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today provided an update on its phase 2 clinical trial using investigational drug INM-755 cannabinol (“CBN”) cream for the treatment of patients with epidermolysis bullosa (“EB”). Based on safety data of the first five adult patients who completed the phase 2 study, an independent data monitoring committee agreed it is safe to allow the enrollment of adolescent patients, defined as persons aged twelve to seventeen with EB. “We are pleased that the initial safety data from InMed’s phase 2 EB clinical trial has allowed the inclusion of adolescent patients,” said Alexandra Mancini, senior vice president of clinical and regulatory affairs at InMed. “With the inclusion of adolescents and increased number of patients available for screening, the target remains to complete enrollment of 20 patients in 2022.”

Receive SMS Text Alerts from CanadianCannabisWire

Text "CCWIRE" to 844-397-5787

(US Mobile Phones Only)

Featured Event

Grow Up Conference
9/12 - 9/14 – Niagara Falls, ON

Join us in spectacular Niagara Falls, ON for 3 days of cannabis cultivation and extraction.

Join top growers, suppliers, manufacturers, extraction equipment/services, hundreds of top speakers/keynotes and thousands of delegates together to bring you up-to-date on proven methods, innovations and technology. This year’s expo will include the Grow Up Extraction Zone.

Learn from over 100 cannabis cultivation and extraction experts at our 3 day conference.

Grow Up Conference and Expo is focused on the education, collaboration and growth of the cannabis growing industry. Meet licensed producers, suppliers, equipment manufacturers, investors, lawyers, government officials and growing enthusiasts – all in one magnificent location.

Meet old friends and create new relationships at Grow Up's famous Meet the Exhibitors networking party.

Upcoming Events

• NECANN’s New Jersey Convention — Atlantic City, NJ — 10/1 - 10/2
• NECANN's Maine Convention — Portland, ME — 10/15 - 10/16
• Alternative Products Expo, Chicago — Chicago — 11/3 - 11/5

About CanadianCannabisWire (CNW)

CanadianCannabisWire (CCW) is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. Leveraging a professional team of journalists and writers, CCW introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network of over 5,000 key distribution outlets. Cutting through information overload, CCW's innovative and proprietary systems clearly and succinctly deliver its clients much needed visibility, recognition and brand awareness. CCW is where news, content and information converge.